This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By integrating digitization and machine learning, there is an opportunity to deliver personalized care to all patients and scale precision dosing with minimal physician involvement, maximizing the effectiveness and accessibility of these drugs. appeared first on MedCity News.
Graphite Bio voluntarily paused a Phase 1/2 test of its gene-edited therapy for sickle cell disease after the first patient in the study developed a serious blood complication. The setback will also delay plans to reach the clinic with another genetic medicine in its pipeline.
In fact, the research shows that those who were on semaglutide were less likely to have suicidal thoughts than patients on other diabetes and obesity meds.
Liver complications are a known sideeffect risk of Zolgensma and other genetic medicines that are delivered by engineered viruses. The two deaths reported following treatment with Novartis’s Zolgensma mark the first fatal cases of acute liver failure associated with the gene therapy.
For patients who may be unable to afford the high cost of GLP-1 obesity drugs or are worried about the sideeffects, it’s important for healthcare providers to offer education on herbal alternatives and consider these as part of the broader treatment conversation. appeared first on MedCity News.
SGAs used to treat bipolar disorder are often effective at helping young patients’ mental health improve but can have significant sideeffects including elevated blood pressure and glucose, increased appetite, as well as weight gain. Metformin is typically used for Type II diabetes treatment.
By catching the disease early, patients have a higher chance of receiving successful treatment, and the cost of treatment can be significantly reduced. Personalized treatment plans: Treatment plans can vary widely depending on the type of cancer, the stage and the patient’s overall health.
New research from the US indicates that a prophylactic treatment before immunotherapy can significantly reduce the rate of cytokine release syndrome (CRS) in multiple myeloma patients. Immunotherapy drugs like teclistamab can result in potentially fatal sideeffects, including CRS and immune cell-associated neurotoxicity syndrome (ICANS).
OPENING: TV is great at creating awareness, but it can also scare patients away if one of your sideeffects is “may lead to death.” ” I understand that DTC marketers are in love with TV even though it’s becoming less effective. On top of these sideeffects is the common sideeffect of diarrhea.
In addition, the patient journey is different for each product category and audience. The hottest pharma product is Lilly’s diabetes drug, hyped by the media as helping patients lose weight. Most of the media stories, however, leave out the possible drug sideeffects, which are serious. TV, alone, is not the answer.
DTC marketers spend a lot of time and money gaining insights into patients and caregivers. That information should be shared with HCPs and insurers to understand better the barriers and opportunities of treating patients. The research showed that patients wanted to understand how the drug works and the potential sideeffects.
Pharma websites, more and more, are becoming less relevant when it comes to intent to ask their doctor about a new drug because they too often are hard to read and don’t answer patients’ questions. Patients want to understand better why their insurance company won’t pay for certain medication or why their co-pay has gone up.
Patients want quick fixes, and the idea of losing some weight because of a new drug is enticing to them. In response, the company has been providing six-month waivers to some insured patients that will cap the drug’s out-of-pocket costs at $25 a month, though the long-term picture of coverage is still in flux. Click to Tweet.
Traditional medicine refers to the knowledge, skills and practices that indigenous and different cultures use to maintain health, encompassing forms such as herbal medicine, Traditional Chinese Medicine (TCM) and acupuncture. Studying the behaviour of animals can aid in drug discovery research too.
What is patient centricity and why is it an important consideration in drug development? Patient centricity is the process of obtaining the patients’ voice and making them active participants; identifying their needs and utilising them to improve decision-making in the healthcare arena.
According to a study in the Journal for American Board of Family Medicine “respondents (76%) said they were likely to ask a health care provider about advertised drugs; 26% said they had already done so. Any discussion around DTC should acknowledge the following: 1ne: DTC is more effective for some health categories than others.
Imagine a medicine that reduced the death rate of breast cancer and risk of recurrent breast cancer by 50% lowered the risks of colon cancer and type 2 diabetes by two-thirds, and those of heart disease, hypertension, and Alzheimer’s’ disease by 40%. But… Only 23% of Americans Get Enough Exercise.
A major limitation is that these drugs generally do not target the specific causes of neuropathic pain, and their efficacy is reduced when the underlying conditions, like nerve damage, cannot be treated effectively. What are the key current challenges in the development of pain medicines? Internet] NIH. cited 2024Jan].
The Medicines and Healthcare products Regulatory Agency (MHRA) aims to launch a pilot genetic biobank that will gather patient data to associate drug-related adverse events to their genetic makeup. Sideeffects due to drugs are responsible for one in every 16 hospital admissions in the UK, based on the announcement.
Do you want your employer, or your insurance company, or anyone else to know you’re on anti-depressants, HIV medication, Viagra, or that you regularly get medicine for genital warts? When you use GoodRx, ALL that data regarding your prescription transaction is collected and stored. GoodRx employs people to dig into it analyze it.
Kesselheim, a professor of medicine at Harvard Medical School via the Washington Post , says “the worst thing for people with Alzheimer’s would be to put out a product that doesn’t work.” Knopman, a Mayo Clinic neurologist who treats Alzheimer’s patients and is a member of the FDA advisory committee. Washington Post.
After eight weeks of treatment, patients’ depression severity scores dropped by an average of 19.1 Treatment-related sideeffects included nausea and headache but were generally mild. “As Psychedelic medicines: are they gaining traction in Europe? Participants described generally positive experiences.
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Comirnaty ® , the Pfizer/BioNTech COVID-19 vaccine for infants and children aged six months to four years in Great Britain. The common, expected sideeffects were within expectations for a vaccine in this age group.
“Drugs don’t work in patients who don’t take them,” C. 1 In addition, of patients who began therapy, more than 70% were no longer on their prescribed medication after 12 months. 1 In addition, of patients who began therapy, more than 70% were no longer on their prescribed medication after 12 months. Everett Koop, MD, U.S.
Accessibility, as well as optimised nutrient and medicine release, are the driving forces behind modernising drug delivery. Pills can present significant challenges for certain patients around administration, eg, for those who have difficulty swallowing liquids or solids. Interested? Find out more by completing your details!
Patients with refractory systemic lupus erythematosus (SLE) were able to go into remission within three months of one small dose of a personalised anti-CD19 CAR T-cell immunotherapy in a clinical study. Every patient remained in remission up to a year. CAR T therapy for systemic lupus erythematosus.
The Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have announced that biosimilar medicines authorised in the European Union (EU) can now be interchanged with their reference medicine or an equivalent biosimilar product. New regulatory guidance could lead to UK biosimilar boom.
1 Yet, most patients haven’t tried prescription therapies, a discovery Phreesia Life Sciences made after surveying 6,780 adults age 18 and older who previously had been diagnosed with or treated for constipation as they checked in for their doctors’ appointments. Address Patients’ Quality of Life. Why the disconnect?
The product, produced by biopharma company PTC Therapeutics, is approved for patients 18 months and over. It has been granted marketing authorisation by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. The most common sideeffects observed were initial insomnia, irritability and dyskinesia.
The committee advises that Cibinqo (abrocitinib), Jyseleca (filgotinib), Olumiant (baricitinib), Rinvoq (upadacitinib) and Xeljanz (tofacitinib), used for chronic inflammatory conditions, should have limited distribution to minimise risk of serious sideeffects such as cardiovascular diseases, blood clots, cancer and serious infections.
A new drug, part of a class of chemicals called potassium-channel openers, has demonstrated potential in offering relief to patients with focal epilepsy. Comparatively, patients given a placebo had on average 18 percent fewer seizures during the treatment phase of the trial, which lasted eight weeks.
Precision medicine or next-generation sequencing helps in the faster discovery of drugs and tailored medication for individual patients. . However, in DTC marketing, we should be careful about using AI in an era where too many patients feel like our healthcare system is dehumanizing them. Measuring RNA, DNA quickly.
Researchers at Great Ormond Street Hospital for Children (GOSH) and University College London (UCL) Great Ormond Street Institute of Child Health (UCL GOS ICH) have used “universal” CRISPR-edited cells in humans for the first time to treat B-cell acute lymphoblastic leukaemia (B-ALL) child patients with engineered donor T cells.
PM360 asked industry experts what it takes to be a patient-first organization and how companies can better ensure they are delivering experiences that meet patients’ expectations. Specifically, we asked them: What is required today for life sciences companies to truly practice a patient-first approach? Matt Flesch.
“People adhere to medicines at a scale that should bewilder everyone in healthcare,” exclaims Grace Lomax, Clinical Director of Patient Connect , part of Clarivate. Little wonder 70% of patients with hypertension remain hypertensive and therefore at risk of myocardial infarctions (MIs) and cerebrovascular accidents.
Amgen’s new immunotherapeutic agent Tarlatamab has been shown in a Phase II trial to provide sustained anti-tumour activity in 40 percent of the small cell lung cancer patients. The international DeLLphi-301study was investigated as a new anti-cancer treatment option for patients previously considered to be beyond treatment.
SUMMARY: Value-based healthcare is a healthcare delivery model in which providers, including hospitals and physicians, are paid based on patient health outcomes. Seventy-five percent of Americans have trouble taking their medicine as directed. Americans are not healthy. Then there is health literacy.
In a statement , the health technology assessment (HTA) organisation said that the two drugs were backed after an agreement with the two developers on pricing that will make them an option for around 3,450 NHS patients. NICE estimates that around 2,800 people are eligible for treatment with Piqray plus fulvestrant.
a China-based pharma company has announced it has received clearance for its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate clinical studies of T21, a 3D-printed medicine that can target specific segments in the colon to more safely deliver oral ulcerative colitis (UC) drugs.
A ‘magic bullet’ medicine that can cure a disease quickly and completely, [1] without deleterious sideeffects. [2] In 1897, Ehrlich proposed that certain cells expose a set of side chains on their surface, later termed ‘receptors’, which are associated with specific recognition. [3]
Cala , the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced the commercial launch of its next generation system: the Cala kIQ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease.
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Pfizer’s Litfulo (ritlecitinib) for treatment for severe alopecia areata in patients 12 years and older. A hard capsule medicine, Litfulo is recommended to be taken daily as one 50mg oral dose. Results from this pivotal study showed that 13.4
New results from a first-of-its-kind study reports that a CAR-T cell therapy provided similar efficacy and safety to relapsed or refractory multiple myeloma patients administered with the treatment in clinical trials. Furthermore, 70 percent of these patients had a complete response.
It has been conditionally authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) as a gene-editing therapy for certain patients 12 years old and over with sickle-cell disease and transfusion-dependent β-thalassemia. The agency stated that the gene-editing therapy has the potential to offer “life-long” results.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content